Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1992-1997
Published online before print June 23, 2005, doi: 10.1161/01.ATV.0000174806.76629.7b
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
25/9/1992    most recent
01.ATV.0000174806.76629.7bv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vossen, C. Y.
Right arrow Articles by Rosendaal, F. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vossen, C. Y.
Right arrow Articles by Rosendaal, F. R.
Related Collections
Right arrow Deep vein thrombosis
Right arrow Thrombophilia
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1992.)
© 2005 American Heart Association, Inc.


Thrombosis

Recurrence Rate After a First Venous Thrombosis in Patients With Familial Thrombophilia

Carla Y. Vossen; Isobel D. Walker; Peter Svensson; Juan C. Souto; Inge Scharrer; F. Eric Preston; Gualtiero Palareti; Ingrid Pabinger; Felix J.M. van der Meer; Mike Makris; Jordi Fontcuberta; Jacqueline Conard; Frits R. Rosendaal

From the Department of Clinical Epidemiology (C.Y.V., F.R.R.), Leiden University Medical Center, Leiden, The Netherlands; the Department of Haematology (I.D.W.), Glasgow Royal Infirmary, Glasgow, UK; the Department for Coagulation Disorders (P.S.), University Hospital, Malmö, Sweden; the Department of Haematology (J.C.S., J.F.), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; the Department of Internal Medicine (I.S.), University Hospital, Frankfurt/Main, Germany; the Department of Haematology (F.E.P., M.M.), Royal Hallamshire Hospital, Sheffield, UK; the Department of Angiology and Blood Coagulation (G.P.), University Hospital S. Orsola, Bologna, Italy; the Department of Haematology and Haemostaseology (I.P.), University Hospital Vienna, Vienna, Austria; the Department of Haematology (F.J.M.v.d.M., F.R.R.), Leiden University Medical Center, Leiden, The Netherlands; and the Department of Biological Haematology (J.C.), Hôtel-Dieu Hospital, Paris, France.

Correspondence to Prof F.R. Rosendaal, MD, Department of Clinical Epidemiology, Leiden University Medical Center, PO box 9600, 2300 RC Leiden, The Netherlands. E-mail F.R.Rosendaal{at}lumc.nl

Objective— Few comprehensive data are available on the recurrence rate of venous thrombosis in carriers of thrombophilic defects from thrombophilic families. We prospectively determined the recurrence rate after a first venous thrombotic event in patients with familial thrombophilia attributable to factor V Leiden or deficiencies of protein C, S, or antithrombin.

Methods and Results— Data were gathered during follow-up on the occurrence of risk situations, anticoagulation treatment, and events (eg, venous thrombosis, hemorrhage). Over a mean follow-up period of 5.6 years, 44 of the 180 patients with familial thrombophilia who did not use long-term anticoagulation experienced a recurrent venous thromboembolic event (5.0%/year; 95% CI 3.6 to 6.7) compared with 7 of the 124 patients on long-term anticoagulation (1.1%/year; 95% CI 0.4 to 2.2). Spontaneous events occurred less often in patients on long-term anticoagulation (57%) than in patients without long-term anticoagulation (75%). The highest recurrence rate was found among men with a deficiency in natural anticoagulants or multiple defects and women with antithrombin deficiency. Although long-term anticoagulation treatment decreased the incidence of recurrent events by 80%, it also resulted in a risk of major hemorrhage of 0.8% per year.

Conclusions— Extra care after a first event is required for men with a deficiency in natural anticoagulants or multiple defects and women with antithrombin deficiency.

We prospectively determined the recurrence rate in patients with familial thrombophilia. The overall incidence of a second venous thromboembolic event was 5.0%/year. Extra care after a first event is required for men with a deficiency in natural anticoagulants or multiple defects and women with antithrombin deficiency.


Key Words: familial thrombophilia • incidence • prospective follow-up • recurrence • venous thrombosis




This article has been cited by other articles:


Home page
haematolHome page
C. Laczkovics, H. Grafenhofer, A. Kaider, P. Quehenberger, R. Simanek, C. Mannhalter, K. Lechner, and I. Pabinger
Risk of recurrence after a first venous thromboembolic event in young women
Haematologica, September 1, 2007; 92(9): 1201 - 1207.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
J. A. Heit
Thrombophilia: Common Questions on Laboratory Assessment and Management
Hematology, January 1, 2007; 2007(1): 127 - 135.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
M. Cushman
Inherited Risk Factors for Venous Thrombosis
Hematology, January 1, 2005; 2005(1): 452 - 457.
[Abstract] [Full Text] [PDF]